Vaccine and Infectious Disease Division, University of Washington, Seattle, United States
Elizabeth R Duke
Vaccine and Infectious Disease Division, University of Washington, Seattle, United States; Department of Medicine, University of Washington, Seattle, United States
Christopher W Peterson
Department of Medicine, University of Washington, Seattle, United States; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, United States; Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, United States
Vaccine and Infectious Disease Division, University of Washington, Seattle, United States
Bryan T Mayer
Vaccine and Infectious Disease Division, University of Washington, Seattle, United States
Hans-Peter Kiem
Department of Medicine, University of Washington, Seattle, United States; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, United States; Stem Cell and Gene Therapy Program, Fred Hutchinson Cancer Research Center, Seattle, United States; Department of Pathology, University of Washington, Seattle, United States
Vaccine and Infectious Disease Division, University of Washington, Seattle, United States; Department of Medicine, University of Washington, Seattle, United States; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, United States
Autologous, CCR5 gene-edited hematopoietic stem and progenitor cell (HSPC) transplantation is a promising strategy for achieving HIV remission. However, only a fraction of HSPCs can be edited ex vivo to provide protection against infection. To project the thresholds of CCR5-edition necessary for HIV remission, we developed a mathematical model that recapitulates blood T cell reconstitution and plasma simian-HIV (SHIV) dynamics from SHIV-1157ipd3N4-infected pig-tailed macaques that underwent autologous transplantation with CCR5 gene editing. The model predicts that viral control can be obtained following analytical treatment interruption (ATI) when: (1) transplanted HSPCs are at least fivefold higher than residual endogenous HSPCs after total body irradiation and (2) the fraction of protected HSPCs in the transplant achieves a threshold (76–94%) sufficient to overcome transplantation-dependent loss of SHIV immunity. Under these conditions, if ATI is withheld until transplanted gene-modified cells engraft and reconstitute to a steady state, spontaneous viral control is projected to occur.